Zoetis (NYSE:ZTS) has been given a $78.00 price target by investment analysts at BMO Capital Markets in a research note issued to investors on Monday. The firm presently has a “hold” rating on the stock. BMO Capital Markets’ target price indicates a potential upside of 1.80% from the company’s current price.
Several other equities research analysts have also weighed in on ZTS. Cantor Fitzgerald restated a “buy” rating and set a $75.00 price target on shares of Zoetis in a research report on Tuesday, September 26th. BidaskClub lowered Zoetis from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a research report on Thursday, October 12th. Stifel Nicolaus restated a “buy” rating and set a $65.00 price target on shares of Zoetis in a research report on Tuesday, October 24th. Finally, Morgan Stanley lifted their price target on Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the stock. Zoetis currently has a consensus rating of “Buy” and an average price target of $73.72.
Zoetis (NYSE ZTS) traded up $0.29 during midday trading on Monday, hitting $76.62. The company had a trading volume of 4,829,600 shares, compared to its average volume of 2,623,585. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. Zoetis has a one year low of $52.00 and a one year high of $77.03. The company has a market capitalization of $37,760.00, a price-to-earnings ratio of 40.33, a PEG ratio of 1.83 and a beta of 1.06.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period in the previous year, the company posted $0.52 earnings per share. The firm’s revenue was up 8.5% on a year-over-year basis. research analysts predict that Zoetis will post 2.36 EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in ZTS. Franklin Resources Inc. lifted its holdings in shares of Zoetis by 7.7% during the second quarter. Franklin Resources Inc. now owns 11,349 shares of the company’s stock valued at $708,000 after purchasing an additional 816 shares in the last quarter. Mutual of America Capital Management LLC bought a new position in shares of Zoetis during the second quarter valued at $4,198,000. MML Investors Services LLC lifted its holdings in shares of Zoetis by 17.4% during the second quarter. MML Investors Services LLC now owns 6,338 shares of the company’s stock valued at $395,000 after purchasing an additional 938 shares in the last quarter. FIL Ltd bought a new position in shares of Zoetis during the second quarter valued at $20,092,000. Finally, Suntrust Banks Inc. lifted its holdings in shares of Zoetis by 5.7% during the second quarter. Suntrust Banks Inc. now owns 74,747 shares of the company’s stock valued at $4,661,000 after purchasing an additional 4,043 shares in the last quarter. 92.99% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/22/zoetis-zts-given-a-78-00-price-target-at-bmo-capital-markets.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.